Videos

Uday Popat, MD, presented data from a clinical trial that indicated the fractionation of busulfan reduced toxicities among patients with AML and MDS. This data was presented at the 2023 ASCO annual meeting.

At the 2023 ASCO annual meeting, Won Jin Jeon, MD, presented data from a meta-analysis that explored the prognostic value of identifying BCL6 and CD10 variants in the treatment and management of mantle cell lymphoma.

On site at ASCO 2023, Dr Lars Henrik Jensen shares results from the phase 3 NeoCol trial evaluating the addition of neoadjuvant chemotherapy to initial surgery for patients with locally advanced colon cancer.

At the 2023 ASCO annual meeting, Carolina Schinke, MD, discussed updated results from the MonumenTAL-1 trial which indicated that patients with heavily pretreated R/R multiple myeloma had impressive responses to treatment with talquetamab.

Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.

Michael Castro, MD, discusses the results of a retrospective study evaluating the effect proton pump inhibition use may have on survival outcomes of patients with glioblastoma.

Niels W.C.J. van de Donk, MD, PhD, presents 2-year follow-up results from the MajesTEC-1 trial, which indicated that teclistamab demonstrated safety and efficacy among heavily pre-treated patients with R/R multiple myeloma.

Bhagirathbhai R. Dholaria, MBBS, highlights findings from the TRiMM-2 trial, which demonstrated that the combination of talquetamab and daratumumab was safe and effective for patients with R/R multiple myeloma.

Dorota Goplen, MD, Haukeland University Hospital, Bergen, Norway, discusses results from a phase 1b/2 BORTEM-17 study evaluating the efficacy of sequential treatment with bortezomib and temozolomide for patients with glioblastoma and...

At the 2023 ASCO Annual Meeting, Jason Luke, MD, shares results from the protocol-specified final distant metastasis-free survival analysis of KEYNOTE-716, evaluating adjuvant pembrolizumab among patients with stage IIIB and IIIC resected...